Morgan Stanley lowered the firm’s price target on Amwell (AMWL) to $6 from $10.50 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst added in a year-ahead outlook note for the Healthcare Services group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Balanced Outlook on American Well: Optimism Amidst Caution with Strategic Shifts and Contract Dependencies
- Amwell management to meet virtually with BTIG
- Amwell’s Earnings Call: Mixed Results and Strategic Focus
- Amwell price target lowered to $7 from $10 at TD Cowen
- Amwell price target lowered to $6 from $8 at Stifel